COSMO Pharmaceuticals SA (COPN) - Total Liabilities
Based on the latest financial reports, COSMO Pharmaceuticals SA (COPN) has total liabilities worth CHF123.36 Million CHF (≈ $155.96 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore COSMO Pharmaceuticals SA long-term investment allocation to see how much of total assets are deployed in long-term investments.
COSMO Pharmaceuticals SA - Total Liabilities Trend (2004–2025)
This chart illustrates how COSMO Pharmaceuticals SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see COSMO Pharmaceuticals SA total assets.
COSMO Pharmaceuticals SA Competitors by Total Liabilities
The table below lists competitors of COSMO Pharmaceuticals SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Triumph Financial, Inc.
NASDAQ:TFIN
|
USA | $5.44 Billion |
|
Rami Levi
TA:RMLI
|
Israel | ILA4.14 Billion |
|
Shoals Technologies Group Inc
NASDAQ:SHLS
|
USA | $262.15 Million |
|
Bitfarms Ltd.
NASDAQ:KEEL
|
USA | $735.97 Million |
|
Cairn Homes PLC
IR:C5H
|
Ireland | €522.49 Million |
|
ZWSOFT Guangzhou Co Ltd
SHG:688083
|
China | CN¥561.65 Million |
|
Sino Wealth Electronic Ltd
SHE:300327
|
China | CN¥328.69 Million |
|
Beijing Urban Construction Investment & Development Co Ltd
SHG:600266
|
China | CN¥78.25 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down COSMO Pharmaceuticals SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is COSMO Pharmaceuticals SA's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COSMO Pharmaceuticals SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COSMO Pharmaceuticals SA (2004–2025)
The table below shows the annual total liabilities of COSMO Pharmaceuticals SA from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF123.36 Million ≈ $155.96 Million |
-12.93% |
| 2024-12-31 | CHF141.68 Million ≈ $179.12 Million |
+13.40% |
| 2023-12-31 | CHF124.94 Million ≈ $157.96 Million |
-57.76% |
| 2022-12-31 | CHF295.80 Million ≈ $373.98 Million |
+1.00% |
| 2021-12-31 | CHF292.88 Million ≈ $370.28 Million |
+49.40% |
| 2020-12-31 | CHF196.04 Million ≈ $247.84 Million |
+2.41% |
| 2019-12-31 | CHF191.43 Million ≈ $242.02 Million |
+5.86% |
| 2018-12-31 | CHF180.83 Million ≈ $228.62 Million |
+549.14% |
| 2017-12-31 | CHF27.86 Million ≈ $35.22 Million |
-0.21% |
| 2016-12-31 | CHF27.92 Million ≈ $35.29 Million |
-18.60% |
| 2015-12-31 | CHF34.30 Million ≈ $43.36 Million |
-53.23% |
| 2014-12-31 | CHF73.33 Million ≈ $92.71 Million |
+220.94% |
| 2013-12-31 | CHF22.85 Million ≈ $28.89 Million |
-16.13% |
| 2012-12-31 | CHF27.24 Million ≈ $34.44 Million |
+86.55% |
| 2011-12-31 | CHF14.60 Million ≈ $18.46 Million |
-56.35% |
| 2010-12-31 | CHF33.46 Million ≈ $42.30 Million |
+186.73% |
| 2009-12-31 | CHF11.67 Million ≈ $14.75 Million |
-19.68% |
| 2008-12-31 | CHF14.53 Million ≈ $18.37 Million |
+20.26% |
| 2007-12-31 | CHF12.08 Million ≈ $15.27 Million |
-33.86% |
| 2006-12-31 | CHF18.27 Million ≈ $23.09 Million |
-33.77% |
| 2005-12-31 | CHF27.58 Million ≈ $34.87 Million |
+13.30% |
| 2004-12-31 | CHF24.34 Million ≈ $30.78 Million |
-- |
About COSMO Pharmaceuticals SA
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more